Locally Advanced Cervical Cancer Phase 2 Study Publishes Positive Results

PDS Biotechnology Corporation today announced updated data from the Phase 2 clinical trial evaluating Versamune® HPV (PDS0101) with chemoradiation to treat locally advanced cervical cancer were presented at the American Society for Radiation Oncology Annual Meeting 2024.

The company stated 100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8), and 88% (15/17) of patients had a complete metabolic response.

“We are pleased that data from the Phase 2 IMMUNOCERV trial demonstrate compelling clinical activity and a promising safety profile,” said Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech, in a press release on October 2, 2024.

“Based on our continued research in various HPV-positive cancers, Versamune® HPV appears to work in combination with a variety of therapeutic agents to generate clinical responses and promote improved survival in patients with minimal toxicity. We look forward to the next steps in the development of Versamune® HPV for locally advanced cervical cancer.”

PDS Biotech’s oncology pipeline leverages the Versamune® platform and Versamune® plus PDS01ADC in combination with proprietary tumor-specific proteins or peptides (antigens) in developing targeted cancer immunotherapies.